Oslo, Norway, 15 of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%. Telephone conference (online registration): https://register-conf.media-server.com/register/BI65266ce5abba480f9cda4180274c996b The conf ...